Eli Lilly has taken a significant stride forward in India’s neurological care landscape by receiving approval from the Central Drug Standard Control Organisation (CDSCO) for donanemab in adults with early Alzheimer’s disease. The regulatory green light puts Lilly at the vanguard of India’s rapidly evolving dementia treatment ecosystem, particularly as the country prepares for a significant increase in Alzheimer’s cases over the coming decade.
This represents a significant advancement for individuals suffering from early stages of Alzheimer’s disease.
CDSCO’s approval is for patients who have mild cognitive impairment (MCI) or mild Alzheimer’s dementia, as long as they have shown signs of amyloid pathology, which is a key characteristic of the disease. Amyloid is a naturally occurring protein; nevertheless, in some people, it accumulates improperly and produces amyloid plaques. These plaques disrupt communication between brain cells, which directly contributes to memory loss, disorientation, and decreased ability to execute daily tasks.
How Does Donanemab Work? Slowing Cognitive Decline from Its Source
Donanemab is classified as a disease-modifying therapy (DMT), which is a type of medicine that is intended to influence the trajectory of the disease rather than just manage symptoms. It helps the body eliminate extra amyloid plaques from the brain. Clinical trials indicate that minimising this accumulation helps prevent memory deterioration.
• It demonstrates the ability to plan, solve problems, make decisions, and perform daily functional skills.
These are the talents that patients with Alzheimer’s often lose early on, impairing key daily activities such as meal preparation, financial management, and appointment recall.
Industry Leaders Welcome a New Therapeutic Option.
“The approval of donanemab represents an important step in our mission to meet the urgent needs of people living with Alzheimer’s disease in India,” stated Winselow Tucker, President and General Manager of Lilly India. “By providing an innovative therapy that targets amyloid plaques and slows cognitive decline, we hope to give patients and their families more time and a higher quality of life.”
With India’s rapidly ageing population, Alzheimer’s accounts for 60-70% of all dementia cases worldwide; however, the disease is frequently underdiagnosed in the country. By 2030, an estimated 8 million Indians could be living with dementia, posing a significant emotional, social, and economic strain on families. Early detection and quick access to treatment will be critical in reducing long-term consequences.
Safety Profile and Clinical Considerations.
While donanemab represents a significant scientific advancement, it should be used with prudence. The medication is administered via intravenous infusion every four weeks and may produce amyloid-related imaging abnormalities (ARIA), which in some people might result in brain swelling or tiny bleeding. Infusion-related responses also occur, necessitating constant medical observation.
Enhancing Lilly’s Strategic Position in India’s Alzheimer’s Care Pathway
With CDSCO approval, Lilly is now in a stronger position to play a key role in India’s growing Alzheimer’s treatment model. By introducing a cutting-edge therapy to the market, the company demonstrates its long-term dedication to neurological innovation and better patient results.
Donanemab’s arrival is a watershed moment—not only for India’s healthcare system, but also for families searching for hope in the face of a severe, life-altering cancer.